Shilanski & Associates Inc. Invests $216,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Shilanski & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 9,789 shares of the company’s stock, valued at approximately $216,000.

A number of other hedge funds also recently made changes to their positions in TEVA. Diversify Advisory Services LLC increased its stake in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after buying an additional 496 shares during the period. Sanctuary Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after acquiring an additional 805 shares during the last quarter. DGS Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the period. Finally, Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent analyst reports. UBS Group upped their price target on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.63.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $21.75 on Friday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 1 year low of $11.48 and a 1 year high of $22.80. The firm has a 50-day moving average of $19.53 and a 200 day moving average of $18.32.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.